Alligator Bioscience

Share Issue/Capital Change • Dec 20, 2024

ALLIGATOR BIOSCIENCE AB ANNOUNCES OUTCOME OF EXERCISE OF WARRANTS SERIES TO 9

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

The exercise period for warrants series TO 9 in Alligator Bioscience AB ("Alligator Bioscience" or the "Company") ended on 18 December 2024. A total of 1,498,157 warrants were exercised for the subscription of 1,498,157 new ordinary shares, corresponding to an exercise rate of approximately 1.5 percent.

The exercise period for warrants series TO 9 took place during the period 4 – 18 December 2024. One (1) warrant series TO 9 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 0.55 per share. A total of 1,498,157 warrants were exercised, corresponding to approximately 1.5 percent of all warrants series TO 9, for the subscription of a total of 1,498,157 ordinary shares. Through the exercised warrants, Alligator Bioscience will thus receive approximately 0.8 MSEK before issue costs.

Through the warrant exercise, the number of shares in Alligator Bioscience increases by 1,498,157 ordinary shares, from a total of 758,989,086 shares to 760,487,243 shares, of which 759,708,074 are ordinary shares and 779,169 are series C shares. The share capital increases by SEK 1,198.5256 to SEK 608,389.7944. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 0.2 percent based on the number of shares in Alligator Bioscience after the exercise of warrants. The total number of votes in the Company after the exercise of the warrants amounts to 759,785,990.9.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into ordinary shares within approximately three (3) weeks.

Advisers

Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact:

Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact person set out above, at 1:00 p.m. CET on December 20, 2024.

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Alligator has only been made through the prospectus published by Alligator on 15 March 2024, and through the supplement prospectus published by Alligator on 22 March 2024. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company's website, www.alligatorbioscience.com.

Since Alligator Bioscience conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of ordinary shares may require review by the Inspectorate of Strategic Products (ISP). The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company's website, www.alligatorbioscience.com.

Attachments

Alligator Bioscience AB announces outcome of exercise of warrants series TO 9